-
Uncategorized4 weeks ago
Sanofi and Wave post AATD updates in race to end genetic disease’s 40-year new treatment drought
Sanofi and Wave Life Sciences are using their time at the annual meeting of the American Thoracic Society in Orlando to share updated data for their...
-
Uncategorized4 weeks ago
AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs
Baxfendy, the first aldosterone synthase inhibitor to be approved by the FDA for high blood pressure, is among the products AstraZeneca is relying on to hit...
-
Uncategorized4 weeks ago
Prasad ally Szarama exits CBER after 3 weeks as FDA cleanout continues
After less than three weeks on the job, Katherine Szarama is being replaced by Karim Mikhail as acting head of the Center for Biologics Evaluation and...
-
Uncategorized4 weeks agoTexas is opening up a detransition clinic
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. Glad you’re here. Lots of news...
-
Uncategorized4 weeks ago
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
-
Uncategorized4 weeks agoCytiva’s transcient cell line receives FDA AMT designation
The US Food and Drug Administration (FDA) has given an advanced manufacturing technology (AMT) designation to Cytiva’s transient cell line, making it one of the first gene therapy...
-
Uncategorized4 weeks ago
Regeneron’s Phase 3 skin cancer miss adds to mounting failures in LAG-3
Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a spate...
-
Uncategorized4 weeks ago
Clinical trial flaws ‘being scaled, not solved’ by AI: report
Clinical trial data company Phesi’s new analysis found that fewer than one in three trial protocols are connected to documented patient data and outcomes, highlighting the...
-
Uncategorized4 weeks ago
FDA approves AstraZeneca’s baxdrostat for certain patients with hypertension
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday....
-
Uncategorized4 weeks ago
The future of radiopharma is being built by nuclear geeks in SLC
Nusano will bring a massive new radioisotope facility in Salt Lake City online by the end of the year, establishing a supply of starting materials for...
STAT+: Up and down the ladder: The latest comings and goings
FDA imposes import alert on Indian plant after inspectors flag GMP failings
